XtalPi Holdings Limited Issues Profit Warning for First Half of 2026
Key Highlights from the Announcement
- Significant Shift from Profit to Loss: XtalPi Holdings Limited expects to report a net loss attributable to equity holders between RMB215.0 million and RMB275.0 million for the six months ended 30 June 2026. This is a substantial reversal from the net profit of RMB82.8 million recorded during the same period in 2025.
- Revenue Decline Due to High Comparison Base: Projected revenue for the Reporting Period is between RMB380.0 million and RMB400.0 million, down from RMB517.1 million in the corresponding period last year. The sharp decline is mainly due to a large initial payment from a major pipeline licensing project recognized in 2025, which created an exceptionally high base.
- Ongoing Revenue Streams: During the Reporting Period, the Group received a second payment of USD19.0 million (approximately RMB129.4 million) from the same licensing project, recognized as revenue for drug discovery solutions.
- Strong Underlying Growth (Excluding One-off Impact): Excluding the licensing project, underlying business revenue is expected to be no less than RMB250.0 million, representing a year-on-year increase of over 65%. Notably, the AI for Science intelligent solutions business is expected to deliver revenue of at least RMB180.0 million, up more than 120% year-on-year—driven by client expansion, high repeat purchase rates, and technological upgrades.
- Substantial Increase in R&D Expenses: Research and development expenses are projected to reach at least RMB340.0 million, a year-on-year increase of more than 50%. This growth is attributed to continued investment in autonomous laboratories, agentic systems, and the development of multimodal technology platforms and pipelines.
- Strategic Direction: The Group is advancing towards a comprehensive AI-driven proprietary R&D system, highlighted by the launch of “XtalPi Science,” an open intelligent R&D platform for scientific research scenarios, which has intensified investment in autonomous labs and agentic systems.
- Long-Term Potential: XtalPi has established five major technology platforms in drug R&D—small molecules, large molecules, molecular glues, peptides, and oligonucleotides—believed to offer significant long-term commercialization prospects.
- Results Not Yet Audited: The interim results are still being finalized and have not been reviewed by the audit committee or external auditors. Actual results may differ from these preliminary figures.
- Upcoming Interim Results Announcement: The Company expects to publish its interim results by the end of August 2026.
Price-Sensitive Insights for Shareholders
- The shift from profit to a substantial loss in H1 2026 is a material event and could potentially exert downward pressure on the share price.
- The revenue decline is mainly due to the absence of a large one-off payment recognized last year, not a deterioration in core business operations. Underlying businesses, especially AI for Science solutions, are exhibiting robust growth.
- Elevated R&D expenses, while negative for short-term profitability, are aligned with the company’s strategy to build long-term value through innovation and technology leadership.
- Investors should monitor the final audited results for any deviations from these preliminary figures and assess the progress of the company’s strategic investments and new technology platforms.
Management Statement & Caution
The Board believes that continued investments in R&D and technology platforms will strengthen the Group’s capabilities and support sustainable revenue growth over the long term.
Shareholders and potential investors are urged to exercise caution when dealing in the Company’s securities. Seek advice from professional or financial advisers if needed.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. The information is based on the Company’s preliminary announcement and may be subject to change upon release of audited results.
晶泰科技控股有限公司2026年上半年發盈警
公告重點摘要
- 由盈轉虧：晶泰科技預期截至2026年6月30日止六個月錄得歸屬於股東的淨虧損約人民幣2.15億元至2.75億元，較2025年同期錄得的人民幣8,280萬元淨利潤有明顯逆轉。
- 收入因高基數大跌：報告期內預計收入約為人民幣3.8億元至4億元，遠低於去年同期的人民幣5.171億元。主要因去年有一項重大管線授權項目確認首期付款，形成高基數效應。
- 持續收入來源：報告期內，該授權項目按協議收到第二期付款1,900萬美元（約合人民幣1.294億元），已確認為藥物發現解決方案收入。
- 核心業務高速增長：扣除授權項目影響，報告期內核心業務收入預計不少於人民幣2.5億元，按年增長超過65%。其中AI for Science智能解決方案業務收入預計不少於人民幣1.8億元，按年增長超過120%，受惠於新客戶拓展及高客戶複購率。
- 研發開支大增：預計研發費用不少於人民幣3.4億元，按年增長超過50%，主要用於自主實驗室、Agentic系統及多模態技術平台與管線開發。
- 戰略方向明確：公司推進自主AI驅動的研發體系，推出「XtalPi Science」科學開放平台，並加大對自主實驗室和Agentic系統的投資。
- 長遠商業化潛力：已建立涵蓋小分子、大分子、分子膠、肽類及寡核苷酸的五大技術平台，具重大商業化潛力。
- 業績尚未審核：本次盈警為初步預測，未經審核委員會或外部審計師審閱，實際業績或有出入。
- 中期業績將於八月底前公布。
值得股東留意的敏感事項
- 由盈利轉為大額虧損，屬重大消息，或對公司股價帶來壓力。
- 收入下跌主要受去年一次性項目付款影響，非核心業務惡化，核心業務實則高速增長。
- 研發投入大增，雖短期影響盈利能力，但屬於公司技術及長遠價值發展戰略。
- 投資者宜密切留意最終審核業績及公司新技術平台落地進展。
管理層聲明及溫馨提示
董事會認為，持續的戰略投資將鞏固公司研發能力，支持未來收入持續增長。
股東及潛在投資者務必審慎處理公司證券。如有疑問，請諮詢專業顧問。
免責聲明
本文僅供參考，並不構成投資建議。所有資料根據公司初步公告編寫，最終數據以公司審核後公告為準。
